MedTrace Logo

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

NCT05999084 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 735

Last updated 2026-03-11

No results posted yet for this study

Summary

The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Anti-amyloid Monoclonal Antibodies (mAbs)

Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.

COMBINATION_PRODUCT

Standard of Care

The standard of care, other than treatment with anti-amyloid mAbs, provided at the study clinics.

Sponsors & Collaborators

Principal Investigators

  • James J Lah, MD, PhD · Emory University

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-06
Primary Completion
2028-07-31
Completion
2028-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05999084 on ClinicalTrials.gov